drugset / Trial / NCT02140801

Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel

NCT02140801 ↗

RandomizedParallel-groupSingle-blindTreatment

Summary

A number of 352 patients scheduled for elective percutaneous coronary intervention (PCI) with a native coronary stenosis suitable for DES implantation and OCT imaging are openly randomized 1:1 to either BRILINTA™ (ticagrelor) or Plavix® (clopidogrel bisulfate).

Timeline

Start
2014-05-01
Primary completion
2017-03-08
Completion
2017-03-08

Outcome

Met primary endpoint

paper The incidence of subclinical ST in ticagrelor group was significantly low as compared to clopidogrel group (P < .05) at 1-year follow-up. PMID 32326796 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule 75 mg —
Subject Ticagrelor Small molecule 90 mg —

Indications